clinical practice
Seeds of a cure
Research examining Australian plants
as treatments for golden staph, wounds
and more gains funding boost.
By Dallas Bastian
A
ustralian plants may soon help
healthcare professionals combat
golden staph infections, heal
wounds, and even treat diseases such as
Alzheimer’s and Parkinson’s.
Queensland University of Technology
research into the use of plants in
treating these conditions has been
bolstered by $1 million in funding from
an Australian biotech company and the
Commonwealth Government.
The commercial research agreement and
two Commonwealth Research Connection
grants with Health Focus Products Australia
(HFPA) will provide $1,035,614 in funding
over three years to support three areas
of research.
Dr Trudi Collet, from the Indigenous
Medicines Group in the Queensland
University of Technology Institute of Health
and Biomedical Innovation, says the research
will draw upon Australia’s varied flora.
“Australia’s biodiversity is unique and
its application for the treatment of global
infections and diseases has incredible
potential,” Collet says.
She says native plants have a rich history
with Indigenous people and have been
used for a variety of conditions, including
wounds. “Irrespective of where traditional
accounts with regards to the use of
medicinal plants have come from, a lot of
that knowledge [hasn’t] been scientifically
validated for various uses. That’s where my
research comes in,” she says.
One of the projects will explore the use
of three different plants in the treatment
of chronic wounds. The research will
involve isolating the bioactive compounds
from the plants and determining whether
they can enhance cellular proliferation,
increasing the speed of wound healing.
“Globally, more than 7 million people
suffer from a chronic wound, while in
Australia, 433,000 people are diagnosed
each year,” Collet says. “The associated
treatment costs are estimated to be in
excess of $2.6 billion.”
Another project will look into using
a plant to treat golden staph. Similarly,
the researchers will isolate and identify
bioactive compounds. “We have some
preliminary data with regards to this
particular plant, and it is shown to have
exceptional antimicrobial activity against
golden staph,” Collet explains. “The
whole premise of this particular project
is to go ahead and identify the bioactive
compound or compounds that have this
effect against the bacteria.”
She says this could help people with
golden staph infections and chronic wounds
and the professionals who treat them.
“As we know, there’s an increase in
antibiotic resistance,” she says. “There
is also high incidence of golden staph
infections acquired in hospitals and the
community. [Having a novel antibiotic that
can] successfully treat and clear a golden
staph infection will have an enormous
impact, not just within Australia, but on a
global scale as well.”
She adds that the professionals who treat
people with chronic wounds and golden
staph infections will also benefit by seeing
the increased speed of healing.
“The cost associated with managing and
treating a chronic wound are also going to
be decreased,” she says.
Finally, the research will also look into
the treatment of Alzheimer’s disease and
Parkinson’s disease. Collet says this project
will focus on whether particular bioactive
compounds can reduce the progression
of Alzheimer’s and possibly reverse its
effects. She explains that because people
with Parkinson’s often have dementia
as well, there is also potential for a
crossover treatment.
Dr Mark Baldock, HFPA chairman and
founder, says the funding recognises the
research’s value, even at its earliest stages.
“With our ageing population, we are
going to see an increase in health problems
like dementia and chronic wounds, while
the rise in antibiotic-resistant infections is
another concern,” Baldock says. “I was very
excited to hear of this work by Dr Collet.
We have a common goal.”
He says he is hopeful that other biotech
companies will look at offering the same
kind of early-entry research funding. ■
nursingreview.com.au | 21